logo-loader
viewOptiBiotix Health PLC

OptiBiotix set for a strong 2019 as agreements convert into revenues

OptiBiotix Health PLC's (LON:OPTI) Stephen O'Hara looks back on 2018 following the release of their full year results

Among some of the highlights in the period was a five-year deal with Akums Drugs and Pharmaceuticals to exclusively manufacture and supply supplements and drug products containing OptiBiotix’s LPLDL bacteria strain in India.

It also has an exclusive agreement with a US company for the LPLDL that carries six-figure milestone payments.

O'Hara says the raft of agreements signed are now starting to convert to revenues because of the lag period between signing and the start of cash coming in.

Quick facts: OptiBiotix Health PLC

Price: 53 GBX

AIM:OPTI
Market: AIM
Market Cap: £45.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

OptiBiotix Health growing its ProBiotix Health commercial team in Europe

Steve Prescott, CEO of OptiBiotix Health PLC's (LON:OPTI) ProBiotix Health division, speaks to Proactive London while in Europe to meet with some of their key customers and suppliers. Prescott updates on discussions he's having with a major European probiotic company about a new product as...

3 days, 7 hours ago

2 min read